AstraZeneca, Daiichi's breast cancer drug gets FDA nod as first-line treatment

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
MedPage Today on MSN

Blockbuster Drug Lands First-Line Indication for HER2-Positive Breast Cancer

The FDA approved trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pertuzumab (Perjeta) for the first-line ...
Medscape

T-DXd Wins First-Line Indication for HER2+ Breast Cancer

FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
Fierce Pharma

AZ, Daiichi score with FDA nod for Enhertu combo in 1st-line breast cancer

After AstraZeneca and Daiichi Sankyo made waves in June with eye-opening results for Enhertu in a combination treatment for a ...
Zacks Investment Research on MSN

AZN, Daiichi's Enhertu gets FDA nod for first-line breast cancer

AstraZeneca PLC AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has approved their blockbuster antibody ...
MPR

Enhertu Plus Pertuzumab Approved for First-Line HER2+ Breast Cancer

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
PharmExec

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...
Targeted Oncology

Sacituzumab Govitecan: Elevating Quality of Life in First-Line TNBC

Sacituzumab govitecan shows improved survival and quality of life in advanced triple-negative breast cancer, outperforming ...
Applied Clinical Trials Online

ACT Brief: AI-Enabled End-to-End Trials, New Phase III Data in HIV, and a First-Line Shift in HER2-Positive Breast Cancer

In today’s ACT Brief, we close out our McKinsey interview series with a look at how AI could transform clinical trials end to ...
pharmaphorum

Pfizer makes first-line case for Tukysa in breast cancer

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...
Healio

First-line treatment with vedolizumab linked to fewer hospitalizations, surgeries in IBD

Please provide your email address to receive an email when new articles are posted on . Incidences of hospitalizations and surgeries were lowest with the vedolizumab-adalimumab sequence in UC and CD.